Document:

Exhibit 10.1

 

I-Bankers Securities, Inc.

535 5th Ave

Suite 423

New York, New York 10017

Attn.: Mike McCrory, Chief Executive Officer

 

November 6, 2022

 

Ladies and Gentlemen:

 

Reference is made to the letter
agreement, dated February 19, 2020, by and among, East Stone Acquisition Corporation, a British Virgin Islands business company (the “Company”),
Double Ventures Holdings Limited, a British Virgin Islands company (“Double Ventures”), Navy Sail International
Limited, a British Virgin Islands company (“Navy Sail”), Hua Mao, Cheng Zhao, and the directors, officers of
the Company named therein (collectively, the “Lock-up Parties”), as amended by that certain Amendment of Insider
Letter, dated April 15, 2022 (as amended, the “Letter Agreement”). Capitalized terms used but not defined herein
shall have the meanings ascribed to them in the Letter Agreement.

 

Reference is also made to
the underwriting agreement, dated February 19, 2020 (the “Underwriting Agreement”), by and between the Company
and I-Bankers Securities Inc., as Representative (the “Representative”) of the several Underwriters named in
Schedule A thereto, relating to an underwritten initial public offering of the Company’s units.

 

Reference is further made
to that certain Business Combination Agreement, dated April 15, 2022, (i) the Company, (ii) Navy Sail International Limited, a British
Virgin Islands company, in the capacity as the Purchaser Representative thereunder, (iii) NWTN Inc. (“Pubco”),
(iv) Muse Merger Sub I Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned subsidiary
of Pubco, (v) Muse Merger Sub II Limited, a British Virgin Islands business company and a wholly-owned subsidiary of Pubco, and (vi) ICONIQ
Holding Limited, an exempted company incorporated with limited liability in the Cayman Islands, entered into that certain Business Combination
Agreement (as amended from time to time in accordance with the terms thereof, the “Business Combination Agreement”,
and the transactions contemplated thereby, the “Business Combination”).

 

As you are aware, pursuant
to Section 3(a) of the Letter Agreement, the Initial Shareholders agreed not to Transfer any Insider Shares: (x) with respect to 50% of
its Insider Shares, until the earlier of (i) six (6) months after the date of the consummation of the Business Combination or (ii) the
date on which the closing price of the Ordinary Shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends,
reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the Business Combination;
and (y) with respect to the remaining 50% of their Insider Shares, six (6) months after the date of the consummation of the Business Combination,
or earlier, in either case, if, subsequent to the Business Combination, the Company consummates a subsequent liquidation, merger, stock
exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their Ordinary Shares
for cash, securities or other property. Additionally, pursuant to Section 3(b) of the Letter Agreement, the Anchor Investors agreed not
to effectuate any Transfer of securities issued or issuable upon the exercise of the Private Units or their underlying securities until
30 days after the completion of the Business Combination.

 

     

     

    

 

In connection with and in
furtherance of the Business Combination, the Lock-up Parties hereby request that each of the undersigned partially waive compliance by
the applicable Lock-up Parties with Sections 3(a) and 3(b) of the Letter Agreement, as applicable, for the following events contemplated
to occur contemporaneously with the Business Combination:

 

		●	Each of the Anchor Investors shall be released from their
obligations pursuant to Section 3(b) of the Letter Agreement with respect to their Private Units.

 

		●	Double Ventures shall transfer 200,000 of its Insider Shares to Xin Zhang as repayment for a private loan
by Xin Zhang to Mr. Hao to fund a portion of Mr. Hao’s loan to the Company pursuant to that certain promissory note dated February
23, 2021.

 

By signing the counterpart
to this letter, each of the undersigned, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
hereby waives in part the compliance by the Lock-up Parties with Sections 3(a) and 3(b) of the Letter Agreement as described above. Except
as specifically waived herein, the parties to the Letter Agreement retain all rights, and each Lock-up Party retains all obligations,
as set forth in the Letter Agreement, and the Representative retains all rights as set forth in the Underwriting Agreement.

 

[Signature page follows]

 

     

     

    

 

If you are in agreement with the foregoing, kindly indicate
such agreement by signing the counterpart to this letter and returning the signed copy thereof to the Company at the address first written
above or by e-mail at hao@estonecapital.com.

 

	 	Sincerely,
	 	 
	 	Double Ventures Holdings Limited
	 	 
	 	/s/ Chunyi (Charlie) Hao
	 	Name: Chunyi (Charlie) Hao
	 	Title:
	 	 
	 	Navy Sail International Limited
	 	 
	 	/s/ Chunyi (Charlie) Hao
	 	Name: Chunyi (Charlie) Hao
	 	Title: Director
	 	 
	 	/s/ Hua Mao
	 	Hua Mao
	 	 
	 	/s/ Cheng Zhao
	 	Cheng Zhao

 

ACKNOWLEDGED AND AGREED TO THIS 6th DAY OF NOVEMBER 2022:

 

	I-Bankers Securities Inc.	 
	 	 
	/s/ Matthew J. McCloskey	 
	Name: Matthew J. McCloskey	 
	Title: Head of Equity Capital Markets	 
	 	 
	East Stone Acquisition Corporation	 
	 	 
	/s/ Sherman Xiaoma Lu	 
	Name: Sherman Xiaoma Lu	 
	Title: Chief Executive Officer	 

 

 

[Signature Page to
Insider Waiver Letter]EX-10.1

  Exhibit 10.1

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 

  Development and Manufacturing Services Agreement 

  (the “Agreement”) 

  			
	  
	  
	  

	by and between
	  
	  

	  
	  

	Lonza Ltd
	  
	  

	Münchensteinerstrasse 38
	  
	  

	CH-4002 Basel
	  
	  

	Switzerland
	  
	  

	  
	  
	- hereinafter “Lonza” -

	  
	  

	and
	  
	  

	  
	  

	SutroVax Inc.
	  
	  

	400 E Jamie Ct #205
	  
	  

	South San Francisco, CA 94080
	  
	  

	United States
	  
	  

	  
	  
	- hereinafter “Customer” -

  Effective as of October 21, 2016 (the “Effective Date”) 

   

  

  Table of Contents 

   

  							
	  
	  
	  
	  
	  
	  
	  

	  
	  
	  
	  
	Page
	  

	1
	  
	Definitions and Interpretation
	  
	  
	1
	  

	  
	  
	  

	2
	  
	Performance of Services
	  
	  
	5
	  

	  
	  
	  

	3
	  
	Project Management / Steering Committee
	  
	  
	7
	  

	  
	  
	  

	4
	  
	Quality
	  
	  
	7
	  

	  
	  
	  

	5
	  
	Insurance
	  
	  
	8
	  

	  
	  
	  

	6
	  
	Forecasting, Ordering and Cancellation
	  
	  
	8
	  

	  
	  
	  

	7
	  
	Delivery and Acceptance
	  
	  
	10
	  

	  
	  
	  

	8
	  
	Price and Payment
	  
	  
	11
	  

	  
	  
	  

	9
	  
	Capital Equipment
	  
	  
	12
	  

	  
	  
	  

	10
	  
	Intellectual Property
	  
	  
	12
	  

	  
	  
	  

	11
	  
	Warranties
	  
	  
	13
	  

	  
	  
	  

	12
	  
	Indemnification and Liability
	  
	  
	14
	  

	  
	  
	  

	13
	  
	Confidentiality
	  
	  
	15
	  

	  
	  
	  

	14
	  
	Term and Termination
	  
	  
	16
	  

	  
	  
	  

	15
	  
	Force Majeure
	  
	  
	17
	  

	  
	  
	  

	16
	  
	Miscellaneous
	  
	  
	18
	  

  Appendix A 

  Appendix B 

  Appendix C 

   

  

   

   

   

  Recitals 

  WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product; 

  WHEREAS, Lonza and its Affiliates have expertise in the evaluation, development and manufacture of products; 

  WHEREAS, Customer wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement; and 

  WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Customer on the terms and subject to the conditions set out herein. 

  NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the parties intending to be legally bound, agree as follows: 

  1	Definitions and Interpretation 

  

  			
	“Affiliate”
	  
	means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party. “Control” means the ownership of more than fifty percent (50%) of the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.

	  
	  

	“Agreement”
	  
	means this agreement incorporating all Appendices, as amended from time to time by written agreement of the Parties.

	  
	  

	“Applicable Laws”
	  
	means all relevant U.S. and European Union federal, state and local laws, statutes, rules, and regulations which are applicable to a Party’s activities hereunder, including, without limitation, the applicable regulations and guidelines of any Governmental Authority and all applicable cGMP together with amendments thereto.

	  
	  

	“Approval”
	  
	means the first marketing approval by the FDA or EMA of Product from the Facility for commercial supply.

	  
	  

	“Background Intellectual Property”
	  
	means any Intellectual Property either (i) owned or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of this Agreement, and, in the case of Lonza, without use or reliance on Customer Materials or Customer Information, and, in the case of the Customer, without use or reliance on Lonza materials or Lonza Information.

	  
	  

	“Batch”
	  
	means the Product derived from a single run of the Manufacturing Process at a scale to be mutually agreed by the Parties.

	  
	  

	“Batch Price”
	  
	means the Price of each Batch.

	“Campaign”
	  
	means a series of no less than [***] cGMP Batches manufactured consecutively.

	  
	  
	  

	“Cancellation Fee”
	  
	has the meaning given in Clause 6.5.

	  
	  
	  

	“Capital Equipment”
	  
	means those certain pieces of equipment described in the Project Plan: (i) that are specific to the production of the Product and (ii) that are purchased by Customer or for which Customer reimburses Lonza, including, without limitation, the related documentation regarding the design, validation, operation, calibration and maintenance of such equipment.

	  
	  
	  

	“Certificate of Analysis”
	  
	means a document prepared by Lonza listing tests performed by Lonza or approved External Laboratories, the Specifications and test results.

	  
	  
	  

   

  			
	“cGMP”
	  
	means those laws and regulations applicable in the U.S. and Europe, relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including without limitation, ICH Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”, US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC. For the avoidance of doubt, Lonza’s operational quality standards are defined in internal cGMP policy documents.

   

  

   

  

   

   

   

  			
	“cGMP Batches”
	  
	means any Batches which are required under the Project Plan to be manufactured in accordance with cGMP.

	  
	  
	  

	“Change”
	  
	means any change to the Services or pricing incorporated into a written amendment to the Agreement in accordance with clause 16.2 or effected in accordance with the Quality Agreement.

	  
	  
	  

	“Commencement Date”
	  
	means the date of commencement of manufacturing activities for a Batch hereunder.

	  
	  
	  

	“Confidential Information”
	  
	means Customer Information and/or Lonza Information, as the context requires.

	  
	  
	  

	“Customer Information”
	  
	means all technical and other information which at the time of disclosure by Customer was not known to Lonza or in the public domain relating to the Manufacturing Process and the Product, from time to time supplied by the Customer to Lonza, including any materials supplied by Customer to Lonza in accordance with the Project Plan.

	  
	  
	  

	“Customer Materials”
	  
	means any Raw Materials, components of Product, or other materials of any nature provided by Customer.

	  
	  
	  

	“EMA”
	  
	means the European Medicines Agency or any successor agency thereto.

	“Engineering Batches”
	  
	means a Batch that is intended to demonstrate the transfer of the Manufacturing Process to the Facility.

	  
	  
	  

	“External Laboratories”
	  
	means any Third Party instructed by Lonza, with Customer’s prior consent, which is to conduct activities required to complete the Services.

	  
	  
	  

	“Facility”
	  
	means Lonza’s manufacturing facilities in Visp, Switzerland, or such other Lonza facility as may be agreed upon by the Parties.

	  
	  
	  

	“FDA”
	  
	means the United States Food and Drug Administration, or any successor agency thereto.

	  
	  
	  

	“Governmental Authority”
	  
	means any Regulatory Authority and any national, multi-national, regional, state or local regulatory agency, department, bureau, or other governmental entity in the U.S., Switzerland or the European Union.

	  
	  
	  

   

  

  			
	“Intellectual Property”
	  
	means (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered, (ii) all applications (or rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing clause (i) and (iii) and all rights and applications that are similar or equivalent to the rights and application described in the foregoing clauses (i) and (ii), which exist now, or which come to exist in the future, in any part of the world.

	  
	  
	  

   

  			
	“Lonza Information”
	  
	means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or any Affiliate of Lonza to Customer under or in connection with this Agreement, including without limitation, any and all Lonza know-how and trade secrets.

	  
	  
	  

	“Manufacturing Process”
	  
	means the production process provided by Customer for the manufacture of Product, as such process may be improved or modified from time to time by agreement of the Parties in writing.

	  
	  
	  

	“Master Batch Record”
	  
	means the document, proposed by Lonza and approved by Customer, which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product.

	  
	  
	  

	“New Customer Intellectual Property”
	  
	has the meaning given in Clause 10.2.

	  
	  
	  

	“New General Application Intellectual Property”
	  
	has the meaning given in Clause 10.3.

	  
	  
	  

   

   

  

   

   

   

  

  			
	“Party”
	  
	means each of Lonza and Customer and, together, the “Parties”.

	“Price”
	  
	means the price for the Services and Products as set out in Appendix A.

	  
	  

	“Process Validation Batch”
	  
	means a Batch that is produced with the intent to show reproducibility of the Manufacturing Process and is required to complete process validation studies.

	  
	  

	“Product” or “Products”
	  
	means the proprietary molecule identified by Customer as CRM12 (Lonza code: SUO-001) and Polysaccharide + CRM12 Conjugates (Lonza code: SUO-002), to be manufactured using the Manufacturing Process by Lonza for Customer as specified in the Project Plans.

	  
	  

	“Project Plan” or “Project Plans”
	  
	means the plans describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time. The initial Project Plans are attached hereto as Appendix A.

	  
	  

	“Quality Agreement”
	  
	means the quality agreement, attached hereto as Appendix B, setting out the responsibilities of the Parties in relation to quality as required for compliance with cGMP.

	  
	  

	“Raw Materials”
	  
	means all ingredients, solvents, consumables and other components of the Product required to perform the Manufacturing Process or Services set forth in the bill of materials detailing the same (including Resins but excluding any consumables or wearables).

	  
	  

	“Raw Materials Fee”
	  
	means the procurement and handling fee of [***] of the acquisition cost of Raw Materials (save for polysaccharides for conjugation that are provided by Sutrovax) by Lonza that is charged to the Customer in addition to the cost of such Raw Materials. Resins are charged at a fee of [***] as set forth in Clause 8.3.

	  
	  

	“Regulatory Authority”
	  
	means the FDA, EMA and any other similar regulatory authorities as may be agreed upon in writing by the Parties.

	  
	  

	“Release”
	  
	has the meaning given in Clause 7.1.

	  
	  

	“Resin”
	  
	means the chromatographic media and/or UF membranes intended to refine or purify the Product, as specified in the Master Batch Record.

	  
	  

	“Services”
	  
	means all or any part of the services to be performed by Lonza under this Agreement (including, without limitation, process and analytical method transfer, process development, process optimization, validation, clinical and commercial manufacturing, as well as quality control and quality assurance activities), particulars of which are set out in a Project Plan.

	  
	  

	“Specifications”
	  
	means the analytical tests and acceptance criteria of the Product as specified in Appendix C, which may be amended from time to time in accordance with this Agreement.

	  
	  

	“Term”
	  
	has the meaning given in Clause 14.1.

	  
	  

	“Third Party”
	  
	means any party other than Customer, Lonza and their respective Affiliates.

   

   

  

   

   

   

  In this Agreement references to the Parties are to the Parties to this Agreement, headings are used for convenience only and do not affect its interpretation, references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision, references to the singular include the plural and vice versa, and references to the word “including” are to be construed without limitation. 

  2	Performance of Services 

  2.1	Performance of Services. Subject to Clause 2.3, Lonza shall itself and through its Affiliates, diligently carry out the Services as provided in the Project Plan and use commercially reasonable efforts to perform the Services without any material defect and according to the estimated timelines as set forth in the Project Plan. Lonza shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement. Lonza may subcontract or delegate any of its rights or obligations under this Agreement to perform the Services; provided, that any External Laboratories shall be subject to the same obligations and other provisions contained in this Agreement or any applicable Project Plan, including obligations of confidentiality at least as stringent, and as protective of Customer, as those obligations of confidence and non-use imposed upon Lonza and provided that such External Laboratories shall be subject to obligations to act diligently. Lonza shall not be responsible for analytical lab services performed by External Laboratories. 

  2.2	Technology Transfer. The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the Facility, including implementing the technology transfer plan set forth in Project Plan. Customer shall fully support such technology transfer as reasonably requested by Lonza. 

  2.3	Engineering Batches. Lonza shall manufacture Engineering Batches in accordance with the Project Plan. Customer shall have the- right to make whatever further use of the non-cGMP Engineering Batches as it shall determine, provided that Customer pays for such Batches, such use is not for human use and does not violate any Applicable Laws. Lonza makes no warranty that Engineering Batches will meet cGMP or the Specifications. If Lonza determines that an Engineering Batch does meet cGMP and the Specifications, it will release such Engineering Batch as a cGMP Batch. Regardless of whether any Engineering Batch meets cGMP or the Specifications, Customer shall pay to Lonza the Price for such Engineering Batch that were executed in accordance with mutually agreed plans and meet a mutually agreed specification for bioburden, plus the Raw Materials Fee associated with such Engineering Batches. If the Engineering Batch was not performed in accordance with mutually agreed plans or does not meet the agreed bioburden specification, then Lonza shall bear the costs of replacing the Batch, the Raw Materials and Customer Materials for any replacement Engineering Batch. For each CRM12 batch, the Raw Materials liability may be up to a maximum amount of [***]. For each bioconjugate batch, the Raw Materials liability (i) during storage of each bioconjugate batch is limited to [***], (ii) for manufacturing of each bioconjugate batch is limited to [***] and (iii) per manufacturing campaign is limited to [***]. 

  2.4	cGMP Batches. Lonza will, in accordance with the terms of this Agreement and Quality Agreement, manufacture at the Facility and Release to Customer, cGMP Batches that comply with the Manufacturing Process, cGMP and the Specifications, together with a Certificate of Analysis; provided, however, that cGMP manufacture shall not commence until at least [***] has been manufactured in compliance with cGMP and Specifications. Lonza will bear the risk of replacing any Raw Materials or Customer Materials that were consumed in any cGMP Batch that does not meet the Specifications and is not released to Customer, and after [***], Lonza will bear the risk of replacing any Batch that does not meet the Specifications. For each CRM12 batch, the Raw 

  

  Materials liability may be up to a maximum amount of [***]. (i) during storage of each bioconjugate batch is limited to [***], (ii) for manufacturing of each bioconjugate batch is limited to [***] and (iii) per manufacturing campaign is limited to [***]. Prior to commencement of cGMP manufacturing, Lonza shall review the process assumptions. In the event that there is a material difference in the process assumptions as compared with the process results demonstrated during the manufacture of Engineering Batches, the Parties shall meet to discuss in good faith a revision to the Batch Price to reflect such difference. 

   

  2.5	Process Validation Batches. Lonza shall manufacture and deliver Process Validation Batches as mutually agreed by Parties sufficient to document the operability and reproducibility of the Manufacturing Process and permit the Parties to complete and file the necessary regulatory documents. 

  2.5.1	Prior to commencement of Process Validation Batches, Lonza and Customer shall agree a process validation plan identifying the validation requirements of the Manufacturing Process. All process validation activities are excluded from the Price of Process Validation Batches shall be approved by the Customer in advance and shall be paid for by the Customer at the Price set out in the applicable Project Plan.

  2.5.2	Any regulatory support activities (including pre-Approval inspection) required and agreed to by Customer to support the Approval of the Product from the Facility shall be performed and supported by Lonza as reasonably requested by Customer. All such regulatory support activities are excluded from the Price of Process Validation Batches, shall be approved by the Customer in advance, and shall be paid for by the Customer at the Price set out in the applicable Project Plan. 

  2.6	Supply of Customer Information and Customer Materials. Customer shall supply to Lonza all Customer Information and Customer Materials and other information or materials that may be reasonably required by Lonza to perform the Services. Lonza shall not be responsible for any delays arising out of Customer’s failure to provide such Customer Information, Customer Materials, or other information or materials reasonably required to perform the Services to Lonza, and [***]. Lonza hereby undertakes not to use the Customer Materials or Customer Information (or any part thereof) for any purpose other than the performance of the Services under this Agreement. With respect to any Customer Materials, title shall remain with the Customer and shall not transfer to Lonza. 

  2.7	Raw Materials. Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials. Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder. Upon cancellation of any Batch or termination of the Agreement, all unused Raw Materials shall be paid for by Customer within [***] days of invoice and at Customer’s option will either be (a) held by Lonza for future use for the production of Product, (b) delivered to Customer, or (c) disposed of by Lonza. 

  3	Project Management / Steering Committee 

  3.1	Project Plans. With respect to a new project to be governed by this Agreement, a new Project Plan shall be added by agreement in a writing signed by the Parties and appended to Appendix A. Each Project Plan shall include a description of the Services to be provided, the Product to be manufactured, Specifications, a schedule for completion of the Project Plan, pricing details, and such other information as is necessary for relevant Services. In the event of a conflict between the terms of a Project Plan and this Agreement, the terms of this Agreement will govern. 

  3.2	Project Management. With respect to each Project Plan, each party will appoint a project manager who will be the party responsible for overseeing the Project Plan. 

  

  3.3	Steering Committee. Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. 

  The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities: 

  3.3.1	discuss and seek resolution of issues around management of the Services; 

  3.3.2	agree and monitor deadlines and milestones for the Services; and 

   

  3.3.3	discuss and recommend any changes to the Services (although such changes will not take effect until they have been incorporated into a written amendment to the Project Plan which has been signed by the Parties). 

  3.4	Person in Plant. Customer shall be permitted to have, [***], [***] at the Facility as reasonably requested by Customer, [***] for the purpose of observing, reporting on, and consulting as to the performance of the Services. Such [***] shall be subject to and agree to abide by confidentiality obligations to Third Parties and Lonza’s customary practices and operating procedures regarding persons in plant, and such [***] agrees to comply with all instructions of Lonza’s employees at the Facility. 

  4	Quality 

  4.1	Responsibility for quality assurance and quality control of Product shall be allocated between Customer and Lonza as set forth in the Quality Agreement and in Lonza standard operating procedures. If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail. If the Quality Agreement is not in place at the Effective Date, Lonza and Customer commit to enter into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing. 

  4.2	Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement. 

  5	Insurance 

  5.1	Customer shall, during the Term prior to any clinical use of the Product, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance in the amount of at least [***]. Customer shall at least [***] days prior to the first clinical use of a Product manufactured or Services provided under this Agreement, and for [***] years after delivery of the last such Product, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***]. Lonza shall, during the Term and for [***] years after delivery of the last Product manufactured or Services provided under this Agreement, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***]. Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request. 

  6	Forecasting, Ordering and Cancellation 

  

  6.1	Forecasting. No later than the[***] day of each [***], Customer shall supply Lonza with a written forecast showing Customer’s good faith estimated [***] requirements for Batches for the following [***] month period (the “Forecast”). No later than [***] following Lonza’s receipt of a Forecast, Lonza shall provide written notice to Customer of [***] and shall provide Customer with an estimated production schedule showing the estimated Commencement Date and delivery date of each Batch. The forecast and [***] given in this Section 6.1 shall not be binding on Customer or Lonza. 

  6.2	Purchase Orders. Customer shall place purchase orders binding on Customer for the number of Batches it wishes to order at least [***] months (or earlier as may be [***]) prior to the Commencement Date for such Batches in accordance with Lonza’s most recent response to the Forecast. Each binding purchase order shall be signed by Customer and shall authorize Lonza to manufacture such Batches of the Product as are set forth therein. Lonza shall not be obligated to commence manufacture of any Batch unless and until such written purchase order is accepted in writing by Lonza. Any delivery date set forth in Lonza’s written confirmation of a purchase order shall be an estimated delivery date only. All ordered Batches shall be scheduled in a single Campaign in each calendar year unless otherwise agreed by Lonza. Any additional or inconsistent terms or conditions of any Customer purchase order, acknowledgement or similar standardized form given or received pursuant to this Agreement shall have no effect and such terms and conditions are hereby rejected. 

  6.3	Rescheduling. Lonza shall have the right to reschedule a Commencement Date of any Batch or Campaign upon reasonable prior written notice to Customer, provided that the rescheduled Commencement Date is no earlier or no later than [***] from the Commencement Date originally estimated at the time of Lonza’s acceptance of the binding purchase order, and further provided that Customer is able to provide the necessary Customer Materials. If the Customer requests to change the Commencement Date, Lonza will make all reasonable attempts to accommodate the request; provided, however, in the event that this change would impact other projects scheduled for occupancy in the designated suite or suites, manufacture of the Customer’s Batch or Campaign may be delayed until an adequate time period is available in the Facility schedule. Any such change requested by Customer may result in a rescheduling fee. Any delay requested by Customer of more than [***] shall be considered a cancellation pursuant to Section 6.5. 

  6.4	Cancellation of a Binding Purchase Order for Polysaccharide + CRM12 Conjugates. Customer may cancel a binding purchase order for Polysaccharide + CRM12 Conjugates upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the “Cancellation Fee”): 

  6.4.1	In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; 

  6.4.2	In the event that Customer provides written notice of cancellation to Lonza more than [***] but less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; and 

  6.4.3	In the event that Customer provides written notice of cancellation to Lonza more than [***] but less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; and 

  6.4.4	In the event Customer provides written notice of cancellation more [***] prior to the Commencement Date of a subject Batch, then [***]. 

  6.4.5	Notwithstanding the provisions of this Clause 6.4, Lonza will use commercially reasonable efforts to reschedule its Facility to mitigate any losses from a cancellation, and if Lonza is able to reallocate any reserved capacity for the performance of services for any third party during the applicable period, then Customer’s obligation 

  

  to pay the amounts under Sections 6.4.1, 6.4.2 or 6.4.3, shall be reduced pro-rata based on the use of such capacity for such third party during the applicable period. 

  6.5	Cancellation of a Binding Purchase Order for CRM 12. Customer may cancel a binding purchase order for CRM 12 upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the “Cancellation Fee’): 

  6.5.1	In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; 

  6.5.2	In the event Customer provides written notice of cancellation more than [***] prior to the Commencement Date of a subject Batch, then [***]. 

  Notwithstanding the provisions of this Clause 6.4, Lonza will use commercially reasonable efforts to reschedule its Facility to mitigate any losses from a cancellation, and if Lonza is able to reallocate any reserved capacity for the performance of services for any third party during the applicable period, then Customer’s obligation to pay the amounts under Sections 6.4.1, 6.4.2 or 6.4.3, shall be reduced pro-rata based on the use of such capacity for such third party during the applicable period 

  6.6	Payment of Cancellation Fee. Any Cancellation Fee shall be payable within [***] following the written notice of cancellation associated with the cancelled Batch. Any Cancellation Fee shall include all costs associated with the cancelled Batch, including any Raw Materials. 

   

  6.7	Replacement Project. Notwithstanding the foregoing, Lonza will use commercially reasonable efforts to secure a new project [***] for the cGMP manufacturing space, [***], and then, in such case, the Cancellation Fee for each Batch cancelled that is replaced by a Batch of the new project shall be reduced by an amount equal to [***] of the production fees associated with such replacement Batch. 

  6.8	Preferred Partnership. Customer and Lonza recognize the mutual strategic value of forging a long-term business relationship (hereinafter a “Preferred Partnership”). Reflecting this Preferred Partnership, Customer agrees [***] from the Effective Date of this Agreement to contract exclusively with Lonza for the manufacture of any and all [***] provided that Lonza can manufacture said product a) [***], b) [***], and c) [***]. 

  7	Delivery and Acceptance 

  7.1	Delivery. All Product shall be delivered [***] (as defined by Incoterms® 2010). Lonza shall deliver to Customer the Certificate of Analysis and such other documentation as is reasonably required to meet all applicable regulatory requirements of the Governmental Authorities not later than the date of delivery of Batches (the “Release”). With respect to any Customer Materials, title and risk of loss shall remain with the Customer and shall not transfer to Lonza. With respect to Product, title and risk of loss shall remain with Lonza until Release, and shall transfer to Customer upon Release in accordance with this provision. 

  7.2	Storage. Customer shall arrange for shipment and take delivery of such Batch from the Facility, at Customer’s expense, within [***] after Release or pay applicable storage costs. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***]; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement. In addition to Section 8.2, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage. Notwithstanding anything to the contrary contained in this Agreement, in no event shall Lonza be required to store any Batch for more than [***] 

  

  after Release. Within [***] following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch. 

  7.3	Acceptance/Rejection of Product. 

  7.3.1	Promptly following Release of Batches, Customer shall inspect such Batches and shall have the right to test such Batches to determine compliance with the Specifications. Customer shall notify Lonza in writing of any rejection of a Batch based on any claim that it fails to meet Specifications within [***] of Release, after which time all unrejected Batches shall be deemed accepted. 

  7.3.2	In the event that Lonza believes that a Batch has been incorrectly rejected, Lonza may require that Customer provide to it Batch samples for testing. Lonza may retain and test the samples of such Batch. In the event of a discrepancy between Customer’s and Lonza’s test results such that Lonza’s test results fall within relevant Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall cause an independent laboratory promptly to review records, test data and perform comparative tests and/or analyses on samples of the Product that allegedly fails to conform to Specifications. Such independent laboratory shall be mutually agreed upon by the Parties. The independent laboratory’s results shall be in writing and shall be final and binding save for manifest error. Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules. 

  7.3.3	Lonza shall replace any Batch that failed to conform with the Specifications (a “Failed Batch”), in the event that it is determined (by the Parties or the independent laboratory) that such failure was [***] (“Lonza Responsibility”). If any replacement cGMP Batch provided as replacement for a Failed Batch also fails to conform to the Specifications, then the Steering Committee shall decide in its sole discretion, [***]. Such replacement shall be made as promptly as practicable, in light of available manufacturing capacity, after the confirmation of Lonza Responsibility, and in any case as soon as reasonably possible after confirmation of Lonza Responsibility. Where possible, such replacement Batch shall be manufactured with the next scheduled cGMP Batch or Campaign. [***] acknowledges and agrees that [***] with respect to a Failed Batch that is a Lonza Responsibility [***], and in furtherance thereof, [***]. Lonza shall not be responsible for the cost of Raw Materials or Customer Materials consumed in any Failed Batch except to the extent set forth in this Clause 7.3.3. 

  8	Price and Payment 

  8.1	Pricing for the Services provided by Lonza are set out in, and based on the assumptions and information set out in, the applicable Project Plan. In the event of changes to the Services based on Customer’s request, Customer shall bear all additional costs. 

  8.2	Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value added tax (VAT) and of any other applicable taxes, levies, import, duties and fees of whatever nature imposed by or under the authority of any government or public authority and all such charges applicable to the Services (other than taxes on Lonza’s income) shall be paid by Customer. When sending payment to Lonza, the Customer shall quote the relevant invoice number in its remittance advice. 

  8.3	Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof and [***] upon Release of applicable Batches or completion of applicable Services, unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. All invoices are strictly net and payment must be made within [***] of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim. 

  

  8.4	If in default of payment of any undisputed invoice on the due date, interest shall accrue on any amount overdue at the lesser of (i) rate of [***] per month above the London Interbank Offered Rate (LIBOR) or (ii) the maximum rate allowable by applicable law, interest to accrue on a day to day basis until full payment; and Lonza shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Services and or delivery of Product until all overdue amounts have been paid in full including interest for late payments. 

  8.5	Price adjustments. 

  8.5.1	Not more than once per calendar year, Lonza may adjust the Price in accordance with the [***] for the previous calendar year. The new Price reflecting such Batch Price adjustment shall be effective for any Batch for which the Commencement Date is on or after the date of Lonza’s notice to Customer of the Price adjustment. 

  8.5.2	In addition to the above, the Price may be changed by Lonza, upon reasonable prior written notice to Customer (providing reasonable detail in support thereof), to reflect (i) an increase in variable costs (such as energy or Raw Materials) by more than [***] (based on the initial Price or any previously amended Price), or for a process adjustment or assumption changes, and (ii) any material change in an environmental, safety or regulatory standard that substantially impacts Lonza’s cost and ability to perform the Services. 

  9	Capital Equipment 

  9.1	Any Capital Equipment required for the performance of the Services shall be acquired on terms to be agreed by the Parties prior to commencement of the relevant Services. 

  10	Intellectual Property 

  10.1	Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other Party. 

  10.2	Subject to Clause 10.3, Customer shall own all right, title, and interest in and to any and all Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with Customer or others, in the performance of the Services, to the extent such Intellectual Property is a direct derivative of or improvement to the Product, Customer Materials, Customer Information and/or Customer Background Intellectual Property (collectively, the “New Customer Intellectual Property”). For avoidance of doubt, “New Customer Intellectual Property” shall include any material, processes or other items that solely embody, or that solely are claimed or covered by, any of the foregoing Intellectual Property, but excluding any New General Application Intellectual Property. 

  10.3	Notwithstanding Clause 10.2, and subject to the license granted in Clause 10.5, Lonza shall own all right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza, solely or jointly with Customer, develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services to the extent such Intellectual Property (i) [***], or (ii) [***] (“New General Application Intellectual Property”). For avoidance of doubt, “New General Application Intellectual Property” shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property. 

  10.4	Lonza hereby assigns to Customer all of its right, title and interest in any New Customer Intellectual Property. Lonza shall execute, and shall require its personnel as well as its Affiliates, External Laboratories or other contractors or agents and their personnel involved in the performance of the Services to execute, any documents reasonably required to confirm Customer’s ownership of the New Customer Intellectual Property, and any 

  

  documents required to apply for, maintain and enforce any patent or other right in the New Customer Intellectual Property. 

  10.5	Subject to the terms and conditions set forth herein (including the payment of the Price as required above), Lonza hereby grants to Customer a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property, to research, develop, make, have made, use, sell and import the Product manufactured under this Agreement. 

  10.6	Customer hereby grants Lonza the non-exclusive right to use the Customer Information, Customer Background Intellectual Property and New Customer Intellectual Property during the Term solely for the purpose of fulfilling its obligations under this Agreement; provided, however, that no license is granted to any Customer Background Intellectual Property that is owned or controlled by Sutro Biopharma, Inc. 

  10.7	Customer will have the right to transfer the Manufacturing Process to itself and/or to any Third Party; provided, however, to the extent such technology transfer includes Lonza Confidential Information, or Lonza Background Intellectual Property, such technology transfer shall be subject to [***], and a reasonable royalty and/or licensing fee and terms to be agreed upon by the Parties. [***]. If [***] the Manufacturing Process includes the use of any such additional royalty-bearing Lonza Confidential Information or Lonza Background Intellectual Property, then Customer will pay to Lonza an agreed royalty and/or other agreed payments for the use of Lonza Confidential Information or Lonza Background Intellectual Property. Lonza shall provide reasonably necessary documents to complete such technology transfer, including transfer of New General Application Intellectual Property, if applicable, and, subject to the terms and conditions of this Clause 10.7, Lonza Confidential Information or Lonza Background Intellectual Property, [***] and Customer shall reimburse Lonza for any costs [***] and expenses, provided that the total cost of such assistance (excluding any costs paid to Lonza for the use of Lonza’s Confidential Information or Lonza Background Intellectual Property) will not exceed [***]. 

  11	Warranties 

  11.1	Lonza warrants that: 

  11.1.1	the Services shall be performed in a professional and workmanlike manner and in accordance with all Applicable Laws; 

  11.1.2	Lonza will not knowingly include in the Manufacturing Process any elements that infringe any such intellectual or industrial property rights vested in any Third Party; 

  11.1.3	except with respect to any development services and Engineering Batches, the manufacture of Product shall be performed in accordance with cGMP and will meet the Specifications at the date of delivery; 

   

  11.1.4	it or its Affiliate holds all necessary permits, approvals, consents and licenses to enable it to perform the Services at the Facility; 

  11.1.5	it has the necessary corporate authorizations to enter into and perform this Agreement; 

  11.1.6	Lonza has never been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a (a) or (b) (the “Act”). In the event that during the term of this Agreement, Lonza (i) becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible under the Act; Lonza agrees to promptly notify Customer. Lonza also agrees that in the event that it becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible under the Act, it shall promptly cease all activities relating to this Agreement; 

  

  11.1.7	subject to payment of undisputed invoices, title to all Product and all New Customer Intellectual Property provided to Customer under this Agreement shall pass free and clear of any security interest, lien or other encumbrance in favour of Lonza; and 

  11.2	Customer warrants that: 

  11.2.1	as of the date of this Agreement to the best of the Customer’s knowledge and belief, the Customer has all the rights necessary to permit Lonza to perform the Services without infringing the Intellectual Property rights of any Third Party and the performance of the Services shall not infringe any Third Party Intellectual Property rights; 

  11.2.2	Customer will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third Party that Customer Information and/or Customer Intellectual Property or that the use by Lonza thereof for the provision of the Services infringes any Intellectual Property or other rights of any Third Party; and 

  11.2.3	Customer has the necessary corporate authorizations to enter into this Agreement. 

  11.3	DISCLAIMER: THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES, AND ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  11.4	Debarment. 

  11.4.1	In the event a party receives a notice from the other party (“Defaulting Party”) or otherwise becomes aware that a debarment, suspension, exclusion, sanction, or declaration of ineligibility action has been brought against the Defaulting Party; then the party receiving such notice shall have the right to terminate this Agreement immediately; provided that if such event shall occur, the party receiving such notice shall not have such right of termination. If the Defaulting Party is disputing and defending such action and the Defaulting Party is otherwise able to perform its services in the manner required under this Agreement. 

  11.4.2	Each party shall ensure that it will not knowingly use in any capacity the services of any individual, corporation, partnership or association which has been debarred under 21 U.S.C. Sec. 335a(a) or (b), or listed in the DHHS/OIG List of Excluded Individuals/Entities or the General Services Administration’s Listing of Parties Excluded from Federal Procurement and Non-Procurement Programs. 

  12	Indemnification and Liability 

  12.1	Indemnification by Lonza. Lonza shall indemnify the Customer, its Affiliates, and their respective officers, employees and agents (“Customer Indemnitees”) for any loss, damage, costs and expenses (including reasonable attorney fees) that Customer Indemnitees may suffer as a result of any Third Party claim arising directly out of [***] except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Customer Indemnitees. Notwithstanding the foregoing, Lonza shall have no obligations under this clause 12.1 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under clause 12.2. 

   

  12.2	Indemnification by Customer. Customer shall indemnify Lonza, its Affiliates, and their respective officers, employees and agents (“Lonza Indemnitees”) from and against any loss, damage, costs and expenses (including reasonable attorney fees) that Lonza lndemnitees may suffer as a result of any Third Party claim arising directly out of [***]; except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Lonza Indemnitees. Notwithstanding the foregoing, Customer shall have no 

  

  obligations under this clause 12.2 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under clause 12.1. 

  12.3	Indemnification Procedure. If the Party to be indemnified intends to claim indemnification under this Clause 12, it shall promptly notify the indemnifying Party in writing of such claim. The indemnitor shall have the right to control the defense and/or settlement thereof; provided, however, that (i) the indemnitor must obtain the prior written consent of the indemnitee (not to be unreasonably withheld) before entering into any settlement of such third party claim, and (ii) any indemnitee shall have the right to retain its own counsel at its own expense. The indemnitee, its employees and agents, shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12. The failure to deliver prompt written notice to the indemnitor of any claim, to the extent prejudicial to its ability to defend such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12. 

  12.4	DISCLAIMER OF CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, LOST PROFITS OR LOST REVENUES ARISING FROM OR RELATED TO THIS AGREEMENT, EXCEPT TO THE EXTENT RESULTING FROM FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT AND/OR FOR EITHER PARTY’S BREACH OF ARTICLE 13 HEREOF. 

  12.5	LIMITATION OF LIABILITY. LONZA’S LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE AGGREGATE, [***], EXCEPT TO THE EXTENT RESULTING FROM LONZA’S FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT. 

  13	Confidentiality 

  13.1	A Party receiving Confidential Information (the “Receiving Party”) agrees to strictly keep secret any and all Confidential Information received during the Term from or on behalf of the other Party (the “Disclosing Party”) using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at least commercially reasonable and customary efforts. Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to the Receiving Party, observed by the Receiving Party or its employees, agents, consultants, or representatives, or otherwise learned by the Receiving Party under this Agreement, which the Receiving Party knows or reasonably should know is confidential or proprietary. 

  13.2	Notwithstanding the foregoing, Receiving Party may disclose to any courts and/or other authorities Confidential Information which is or will be required pursuant to applicable governmental or administrative or public law, rule, regulation or order. In such case the Party that received the Confidential Information will, to the extent legally permitted, inform the other Party promptly in writing and cooperate with the Disclosing Party in seeking to minimize the extent of Confidential Information which is required to be disclosed to the courts and/or authorities. 

  13.3	The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information, which: 

  13.3.1	at the time of disclosure was publicly available; or 

  13.3.2	is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party; or 

  13.3.3	as the Receiving Party can establish by competent proof, was rightfully in its possession at the time of disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party; or 

  

   

  13.3.4	is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to Disclosing Party or any other party; or 

  13.3.5	is developed by the Receiving Party independently from and without use of the Confidential Information, as evidenced by contemporaneous written records. 

  13.4	The Receiving party will use Confidential Information only for the purposes of this Agreement and will not make any use of the Confidential Information for its own separate benefit or the benefit of any Third Party including, without limitation, with respect to research or product development or any reverse engineering or similar testing. The Receiving Party agrees to return or destroy promptly (and certify such destruction) on Disclosing Party’s request all written or tangible Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the Receiving Party in its confidential files for record keeping purposes only. 

  13.5	Each Party will restrict the disclosure of Confidential Information to such officers, employees, professional advisers, finance-providers, consultants and representatives of itself and its Affiliates who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement or an applicable financing or acquisition. Both Parties may disclose Confidential Information of the other Party and its Affiliates to potential and actual acquirers provided such disclosure is limited to the terms of this Agreement. Customer also may disclose to its potential and actual: (i) acquirers and (ii) bona fide collaborators in the research, development and commercialization of the Products, the work product provided to Customer by Lonza as a consequence of the provision of the Services. Prior to disclosure to such persons, the Receiving Party shall inform the Disclosing Party and it shall bind its and its Affiliates’ officers, employees, consultants and representatives to confidentiality and non-use obligations no less stringent than those set forth herein. The Receiving Party shall notify the Disclosing Party as promptly as practicable of any unauthorized use or disclosure of the Confidential Information. 

  13.6	The Receiving Party shall at any time be fully liable for any and all breaches of the confidentiality obligations in this Clause 13 by any of its Affiliates or the employees, consultants, potential and actual acquirers, and representatives of itself or its Affiliates. 

  13.7	Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided under this Clause 13 by a Party may cause irreparable harm to the other Party and that money damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach. In the event of any breach and/or threatened breach, then, in addition to all other remedies available at law or in equity, the non-breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the non-breaching Party. 

  14	Term and Termination 

  14.1	Term. This Agreement shall commence on the Effective Date and shall end on the fifth (5th) anniversary of the Effective Date unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the “Term”). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term. 

  14.2	Termination. This Agreement may be terminated as follows: 

  14.2.1	by either Party for any reason upon [***] prior written notice; provided that Lonza may not provide such notice until after [***]. In such an event all cancellation terms in this Agreement shall apply (except, in the case of termination by Lonza pursuant to Clause 14.2.1, the Cancellation Fees shalt not apply), and the Customer 

  

  shall make payments for work commenced and performed under any purchase order(s) by Lonza prior to the termination notice date; 

  14.2.2	by either Party if the other Party breaches a material provision of this Agreement or a Project Plan and fails to cure such breach to the reasonable satisfaction of the non-breaching Party within [***] following written notification of such breach from the non-breaching party to the breaching party; provided, however, that such [***] period shall be extended as agreed by the Parties if the identified breach is incapable of cure within [***] and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure [***]; 

  14.2.3	by either Party, immediately, if the other Party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy or has a receiver appointed for a substantial part of its assets; or 

  14.2.4	by either Party pursuant to Clause 15. 

  14.3	Consequences of Termination. In the event of termination hereunder, Lonza shall be compensated for (i) Services rendered up to the date of termination, including in respect of any Product in-process; (ii) all costs incurred through the date of termination, including Raw Materials costs and Raw Materials Fees for Raw Materials used or purchased for use in connection with the Project Plan; (iii) all unreimbursed Capital Equipment and related decommissioning charges incurred pursuant to Clause 9; (iv) all amounts due under Clause 6.4, without proration of the final calendar year and (v) any applicable Cancellation Fees. In the case of termination by Lonza for Customer’s material breach, Cancellation Fees shall be calculated as of the date of written notice of termination. 

  14.4	Survival. The rights and obligations of each Party which by their nature survive the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Clauses 5, 10-13 and 16 (to the extent relevant). 

  15	Force Majeure 

  15.1	If Lonza is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and gives written notice thereof to Customer specifying the matters constituting Force Majeure together with such evidence as Lanza reasonably can give and specifying the period for which It Is estimated that such prevention or delay will continue, Lonza shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. Provided that, if such Force Majeure persists for a period of [***] or more, Customer may terminate this Agreement by delivering written notice to Lonza. 

  15.2	“Force Majeure” shall be deemed to include any reason or cause beyond Lonza’s reasonable control affecting the performance by Lonza of its obligations under the Agreement, including, but not limited to, any cause arising from or attributable to acts of God, strike, labor troubles, restrictive governmental orders or decrees, riots, insurrection, war, terrorist acts, or the inability of Lonza to obtain any required raw material, energy source, equipment, labor or transportation, at prices and on terms deemed by Lonza to be reasonably practicable, from Lonza’s usual sources of supply. 

  15.3	With regard to Lonza, any such event of Force Majeure affecting services or production at its Affiliates or suppliers shall be regarded as an event of Force Majeure. 

  16	Miscellaneous 

  

  16.1	Severability. If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any way be affected or impaired thereby. The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision which is as far as possible commercially equivalent considering the legal interests and the Purpose. 

  16.2	Amendments. Modifications and/or amendments of this Agreement must be in writing and signed by the Parties. 

  16.3	Assignment. Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza’s obligations contained in this Agreement, but Lonza shall remain fully responsible in respect of those obligations. Neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, provided, however that either Party may assign this Agreement to (i) any Affiliate of such Party or (ii) any third party in connection with the sale or transfer (by whatever method) of all or substantially all of the assets of the business or Product of such Party to which this Agreement relates, whether by merger, consolidation, acquisition or other form of business combination. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. Lonza shall be entitled to sell, assign and/or transfer its trade receivables resulting from this Agreement without the consent of the Customer. 

  16.4	Notice. All notices must be written and sent to the address of the Party first set forth above. All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by facsimile followed by hard copy delivered by the methods under (c) or (d), (c) by prepaid certified or registered mail, return receipt requested, or (d) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a later date stated in the notice. 

  16.5	Governing Law/Jurisdiction. This Agreement is governed in all respects by the laws of [***], without regard to its conflicts of laws principles. The Parties agree to submit to the jurisdiction of the state and federal courts [***]. 

  16.6	Entire Agreement. This Agreement contains the entire agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous agreements with respect to the subject matter hereof. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. Each party acknowledges that an original signature or a copy thereof transmitted by facsimile or by .pdf shall constitute an original signature for purposes of this Agreement. 

   

  

   

   

   

  IN WITNESS WHEREOF, each of the Parties hereto has caused this Development and Manufacturing Services Agreement to be executed by its duly authorized representative effective as of the date written above. 

   

  			
	LONZA LTD

	  

	  

	By:
	  
	/s/ Bart A. M. van Aarnhem

	  
	  
	  

	  
	  
	  

	Name
	  
	Bart A. M. van Aarnhem

	Title
	  
	Senior Legal Counsel

	Date
	  
	26 October 2016

	  
	  
	  

	  
	  
	  

	By:
	  
	  

	  
	  
	  

	  
	  
	  

	Name
	  
	  

	Title
	  
	  

	Date
	  
	  

	  
	  
	  

	SutroVax Inc.

	  

	  

	By:
	  
	/s/ Grant E. Pickering

	  
	  
	  

	  
	  
	  

	Name
	  
	Grant E. Pickering

	Title
	  
	President & CEO

	Date
	  
	October 21, 2016

   

   

  

   

   

   

  APPENDIX A 

  Project Plan A-1 

  [Attached] 

  [***] 

  Project Plan A - 2 

  [Attached] 

  {16 pages omitted} 

  [***] 

   

  

   

  APPENDIX B 

  Quality Agreement 

  [Attached] 

  {37 pages omitted} 

  [***] 

   

  

   

  APPENDIX C 

  Specifications 

  {9 pages omitted} 

  [***] 

   

  

   

   

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 

  FIRST AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY 

  AGREEMENT 

  This First Amendment (“First Amendment”), which comes into effect on January 1, 2017 (the “First Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and SutroVax Inc (“SutroVax”). This First Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the “Original Agreement”). Lonza and Sutrovax, hereafter referred to as a “Party” and collectively as the “Parties.” 

  Whereas: 

  1.	Lonza and SutroVax entered into the Original Agreement, which the Parties now desire to amend; 

  2.	Sutrovax wishes to extend the Original Agreement in order to add the conjugation to the protein development and manufacturing; 

  Parties hereby agree that the following amendments are made pursuant to the Original Agreement: 

  1.	Project Plan A-2 (Polysaccharide + CRM12 Conjugates, Lonza code SUO-002), version 4, dated 04 January 2017 shall be added to Appendix A of the Original Agreement, in addition to the pre-existing Project Plan A-1 (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001). Project Plan A-2 is attached to this First Amendment as Annex 1. 

  2.	All capitalized terms used herein shall have the meaning set forth in the Original Agreement. 

  3.	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this First Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control. 

  4.	No modification of or amendment to this First Amendment, nor any waiver of any rights under this First Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 

  IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this First Amendment, effective as of the First Amendment Effective Date. 

  [Signatures on following page] 

   

  

   

  									
	  
	  
	  
	  
	  
	  
	  
	  
	  

	SUTROVAX INC
	  
	  
	  
	LONZA LTD

	  
	  
	  
	  
	  

	By:
	  
	/s/ Grant E. Pickering
	  
	  
	  
	By:
	  
	/s/ Bart A M. van Aarnhem

	Name:
	  
	Grant E. Pickering
	  
	  
	  
	Name:
	  
	Bart A M. van Aarnhem

	Title:
	  
	President & CEO
	  
	  
	  
	Title:
	  
	Senior Legal Counsel

	  
	  
	  
	  
	  

	By:
	  
	  
	  
	  
	  
	By:
	  
	/s/ Cordula Altekrüger

	Name:
	  
	  
	  
	  
	  
	Name:
	  
	Cordula Altekrüger

	Title:
	  
	  
	  
	  
	  
	Title:
	  
	Senior Legal Counsel

   

   

  

   

  Annex 1 

  Project Plan A-2 

  to 

  Development and Manufacturing Agreement 

  {24 pages omitted} 

  [***] 

   

  

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 

  SECOND AMENDMENT TO DEVELOPMENT AND MANUFACTURING 

  SUPPLY AGREEMENT 

  This Second Amendment (“Second Amendment”), which comes into effect on July 1, 2017 (the “Second Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and SutroVax Inc (“SutroVax”). This Second Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the “Original Agreement”). Lonza and SutroVax, hereafter referred to as a “Party” and collectively as the “Parties.” 

  Whereas: 

  			
	  
	•
	Lonza and SutroVax entered into the Original Agreement, which the Parties now desire to amend; 

   

  			
	  
	•
	SutroVax wishes to extend the Original Agreement in order to add generation of RCB/PCB for 24 S. pneumoniae strains. 

  Parties hereby agree that the following amendments are made pursuant to the Original Agreement: 

  Project Plan A-3 (Generation of RCB/PCB of 24 S. pneumoniae strains, Lonza code SUO-005), version 2, dated 19 June 2017 shall be added to Appendix A of the Original Agreement, in addition to the pre-existing Project Plan A-1 (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001) and Project Plan A-2 (Polysaccharide + CRM12 Conjugates, Lonza code SUO-002); Project Plan A-3 is attached to this Second Amendment as Annex 1. 

  1.	All capitalized terms used herein shall have the meaning set forth in the Original Agreement. 

  2.	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Second Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control. 

  3.	No modification of or amendment to this Second Amendment, nor any waiver of any rights under this Second Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 

   

  IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Second Amendment, effective as of the Second Amendment Effective Date. 

  [Signatures on following page] 

   

  

   

  							
	  
	  
	  
	  
	  
	  
	  

	SUTROVAX INC
	  
	LONZA LTD

	By:
	  
	/s/ Grant E. Pickering
	  
	By:
	  
	/s/ Marina Eiting

	Name:
	  
	Grant E. Pickering
	  
	Name:
	  
	Marina Eiting

	Title:
	  
	President & CEO
	  
	Title:
	  
	PM

	  
	  
	  
	  
	  
	  
	  

	By:
	  
	  
	  
	By:
	  
	/s/ Andreas Brunner

	Name:
	  
	  
	  
	Name:
	  
	Andreas Brunner

	Title:
	  
	  
	  
	Title:
	  
	Director

   

   

  

   

  Annex 1 

  Project Plan A-3 

  to 

  Development and Manufacturing Agreement 

  {11 pages omitted} 

  [***] 

   

  

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 

  THIRD AMENDMENT TO DEVELOPMENT AND MANUFACTURING 

  SUPPLY AGREEMENT 

  This Third Amendment (“Third Amendment”), which comes into effect on September 26, 2017 (the “Third Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and SutroVax Inc (“SutroVax”). This Third Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the “Original Agreement”). Lonza and SutroVax, hereafter referred to as a “Party” and collectively as the “Parties.” 

  Where 

  			
	  
	1.
	Lonza and SutroVax entered into the Original Agreement, which the Parties now desire to amend; 

   

  			
	  
	2.
	SutroVax wishes to extend the Original Agreement in order to add the production of 25 Polysaccharides to the pneumococcal conjugate vaccine project. 

  Parties hereby agree that the following amendments are made pursuant to the Original Agreement: 

  1.	All capitalized terms used herein shall have the meaning set forth in the Original Agreement 

  2.	Project Plan A-4 (cGMP Supply of 25 Polysaccharides for a Multi-Valent Pneumococcal Vaccine, Lonza code SUO-005), version 5, dated September 15, 2017 shall be added to Appendix A of the Original Agreement, in addition to the pre-existing Project Plan A-1 (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001), Project Plan A-2 (Polysaccharide + CRM12 Conjugates, Lonza code SUO-002), version 4, dated 22 December 2016, and Project Plan A-3 (Generation of RCB/PCB of 24 S. pneumonia strains, Lonza code SUO-005), version 2, dated 19 June 2017. Project Plan A-4 is attached to this Third Amendment as Annex 1. 

  3.	The Parties hereby agree that the current definition of “Background Intellectual Property” shall be deleted in its entire and shall be replaced by the following: 

  			
	  
	  
	  

	“Background Intellectual Property”
	  
	means any Intellectual Property either (i) owned, licensed or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of this Agreement, and, in the case of Lonza, without the use or reliance on Customer Materials or Customer Information, and, in the case of the Customer, without use or reliance on Lonza materials or Lonza information.

  4.	The Parties hereby agree that the current definition of “Product” shall be deleted in its entire and shall be replaced by the following: 

  

  			
	  
	  
	  

	“Product”
	  
	means the proprietary molecules identified by Customer in the applicable Project Plan, including: (a) CRM12 (Lonza code: SUO-001); (b) Polysaccharide + CRM12 Conjugates (Lonza code: SUO-002); (c) RCB/PCB of 24 S. pneumoniae strains (Lonza code SUO-005); and (d) 25 Polysaccharides (Lonza code SUO-006).

  5.	The Parties hereby agree that the current definition of “Raw Material Fee” shall be deleted in its entire and shall be replaced by the following: 

   

  			
	  
	  
	  

	“Raw Material Fee”
	  
	means the procurement and handling fee of [***] of the acquisition cost of Raw Materials by Lonza that is charged to the Customer in addition to the cost of such Raw Materials. Resins are charged at a fee of [***] as set forth in Clause 8.3.

  6.	The Parties hereby agree that the current clause 6.5 shall be deleted in its entire and shall be replaced by the following clause: 

  “6.5	Cancellation of a Binding Purchase Order for CRM12 and/or for the manufacturing of polysaccharides Batches. Customer may cancel a binding purchase order for CRM12 and/or for the manufacturing of polysaccharides Betches upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the “Cancellation Fee”):

  6.5.1	In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; 

  6.5.2	In the event Customer provides written notice of cancellation more than [***] prior to the Commencement Date of a subject Batch, then [***]; and 

  6.5.3	Notwithstanding the above, the Parties hereby agree that [***] shall apply with respect to [***], unless Customer [***], in which case [***]. 

  7.	The Parties hereby agree that the current clause 7.2 shall be deleted in its entire and shall be replaced by the following clause: 

  “7.2 Storage. CRM12 and polysaccharide Batches (required intermediates for the production of Conjugate Drug Substances) will be stored at no charge for up to [***] after Release of Conjugate Drug Substances; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement. Except for CRM12 and polysaccharide Batches, Customer shall arrange far shipment and take delivery of such Batch from the Facility, at Customer’s expense, within [***] days after Release or pay applicable storage costs, unless otherwise agreed to by the Parties. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***]; provided that any additional storage beyond [***]) days will be subject to availability and, if available, will be charged to Customer and will be subiect to a separate agreement. In addition to Section 8.2, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage. Unless otherwise agreed to by the Parties, in no event shall Lonza be required to store any Batch for more than [***] calendar days after Release. Within [***] days following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch.” 

  8.	The Parties hereby agree that the current clause 8.3 shall be deleted in its entire and shall be replaced by the following clause: 

  

  “8.3 Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof (the “Initiation Payment”) and [***] upon Release of applicable Batches or completion of applicable Services (the “Completion Payment”), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch at cost plus a fee of [***]. Notwithstanding the above, Parties agree that in the event that Lonza does not complete stages of the IND enabling work (i.e. the stages necessary for Customer to submit the IND application, including in any event the Release of at least one (1) GMP Drug Product Batch plus one (1) month of GMP Drug Product stability testing before 31 December 2019), Lonza shall for any stage that commences after 31 December 2019 or has not been completed by 31 December 2019, invoice the Initiation Payment for Products or Services upon commencement thereof. The Completion Payment for Products or Services shall be invoiced by Lonza either (i) [***] or (ii) on [***]. All invoices are strictly net and payment must be made within [***] days of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement, including those Services to be performed after the Amendment Three Effective Date under Work Plan A-1, Work Plan A-2, Work Plan A-3 and Work Plan A-4.” 

  9.	The Parties hereby agree that the current clause 10.3 shall be deleted in its entire and shall be replaced by the following clause: 

  “10.3 Nowithstanding Clause 10.2, and subject to the license granted in Clause 10.5, Lonza shall own all  right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza, solely or jointly with Custorner, develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services to the extent such Intellectual Property (i) is generally applicable to the development or manufacture of chemieal or biological products or product components, and could reasanably have been made without the use of the Customer Materials, Customer Information, or Customer Baekground Intellectual Property or (ii) is an improvement of or direct derivative of, any Lonza Background Intellectual Praperty (“New General Application Intellectual Property”). For avoidance of doubt, “New General Application Intellectual Property” shall include any material, processes or other items that embody, or that are claimed or covered by, any of theforegoing Intellectual Property.”

  10.	The Parties hereby agree that the current clause 10.5 shall be deleted in its entire and shall be replaced by the following clause: 

  “10.5 Subject to the terms and conditions set forth herein (including the payment of the Price as required above), Lonza hereby grants to Customer a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property, to research, develop, make, have made, use, sell and import the Product.” 

  11.	The Parties hereby agree that the current clause 10.7 shall be deleted in its entire and shall be replaced by the following clause: 

  “10.7 Customer will have the right to transfer the Manufacturing Process to itself, its Affiliates and/or any third Party, provided, however, to the extent such technology transfer includes Lonza Confidential Information, or Lonza Background Intellectual Property, such technology transfer to any Third Party shall be subject to [***], and a reasonable royalty and/or licensing fee and terms to be agreed upon by the Parties. Lonza will not include in the Manufacturing Process any Lonza Confidential Information or Lonza Background Intellectual Property that would require Customer to pay any additional payment and/or royalty to Lonza in order to transfer the Manufacturing Process to itself, its Affiliates and/or any Third Party without first obtaining Customer’s prior written consent and advising Customer as to the royalty structure and any other payment that would apply for the use of such additional technologies. If Customer has provided such consent and the Manufacturing Process includes the use of any such additional payment-bearing or royalty-bearing Lonza Confidential Information or Lonza Background Intellectual 

  

  Property, then Customer will pay to Lonza an agreed royalty and/or other agreed payments for the use of Lonza Confidential Information or Lonza Background Intellectual Property. Lonza shall provide reasonably necessary documents to complete such technology transfer, including transfer of New General Application Intellectual Property, if applicable, and subject to the terms and conditions of this Clause 10.7, Lonza Confidential Information or Lonza Background Intellectual Property, if incorporated into the Manufacturing Process with Customer’s consent, and Customer shall reimburse Lonza for any costs (based on a full-time employee rate for such support) and expenses, provided that the total cost of such assistance (excluding any costs paid to Lonza for the use of Lonza’s Confidential Information or Lonza Background Intellectual Property) will not exceed [***].” 

  12.	The Parties hereby agree that the current clause 14.2.1 shall be deleted in its entire and shall be replaced by the following clause: 

  “14.2.1 by either Party for any reason upon [***] prior written notice; provided that Lonza may not provide such notice until [***]. In such an event all cancellation terms in this Agreement shall apply (except, in the case of termination by Lonza pursuant to Clause 14.2.1, the Cancellation Fees shall not apply), and the Customer shall make payments for work commenced and performed under any purchase order(s) by Lonza prior to the termination notice date.” 

  13.	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Third Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.

  14.	No modification of or amendment to this Third Amendment, nor any waiver of any rights under this Third Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 

  [Signatures on following page] 

   

  

   

  IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Third Amendment, effective as of the Third Amendment Effective Date. 

  								
	SUTROVAX INC.
	  
	  
	  
	LONZA LTD
	  
	  

	  
	  
	  
	  
	  
	  
	  

	By:
	  
	/s/ Grant E. Pickering
	  
	By:
	  
	/s/ Bart A. M. van Aarnhem

	Name:
	  
	Grant E. Pickering
	  
	Name:
	  
	Bart A. M. van Aarnhem

	Title:
	  
	President & CEO
	  
	Title:
	  
	Senior Legal Counsel

	  
	  
	  
	  
	  
	  
	  

	By:
	  
	By:
	  
	/s/Lee Newton

	Name:
	  
	Name:
	  
	Lee Newton

	Title:
	  
	Title:
	  
	Director, Commercial Development

   

   

  

   

  Annex 1 

  Project Plan A-4 

  to 

  Development and Manufacturing Agreement 

  {23 pages omitted} 

  [***] 

   

  

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

  ALL REFERENCES TO THE “FIFTH AMENDMENT” CONTAINED HEREIN SHOULD BE READ AS THE “FOURTH AMENDMENT.”

  FIFTH AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY AGREEMENT

  This Fifth Amendment ("Fifth Amendment"), which comes into effect retrospectively as per 10 June, 2018 (the "Fifth Amendment Effective Date"), is made by and between Lonza Ltd ("Lonza") and SutroVax Inc ("SutroVax"). This Fifth Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax, as amended from time to time (the "Original Agreement''). Lonza and SutroVax, hereafter referred to as a "Party" and collectively as the "Parties."

  Whereas

  			
	  
	1.
	Lonza and SutroVax signed the Original Agreement in October 2016;

   

  			
	  
	2.
	The Parties now wish to change the production of CRM12 from the [***] facility into the [***] facility;

   

  			
	  
	3.
	The current Project Plan A-1 therefore needs to be adjusted and/or partly replaced by a new Project Plan A-1.1, which shall be attached to this Fifth Amendment as Annex 1.

  Parties hereby agree that the following amendments are made pursuant to the Original Agreement:

  			
	  
	1.
	All capitalized terms used herein shall have the meaning set forth in the Original Agreement.

   

  

  					
	  
	2.
	The proposal (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001), version 4.0, dated 21 October 2016 (the "Proposal [***]") attached to the Original Agreement under Appendix A as Project Plan A-1, will be amended as follows:

	  
	  
	The stages 2-C, 2-D, 2-E and 2-F of the Proposal [***] will be replaced by the stages 2-C, 2-D, 2-E and 2-F as further set out in the proposal (cGMP Manufacturing of CRM12 in [***] facility, Lonza code SUO-001), version 1 dated 22nd June 2018 ("Proposal [***]"). This Proposal [***] shall be attached to the Original Agreement under Appendix A as Project Plan A-1.1, in addition to the existing Project Plans. For the avoidance of doubt, the remaining of Proposal [***] does not change and shall remain in full force and effect.

	  
	3.
	In addition to the above, the Parties hereby agree that the following new sub-clause 6.5.3 shall be added to the existing clause 6.5:

	  
	6.5.3.
	The initial campaign in the [***] covering [***] Batches, of which the first Batch will always be an Engineering Batch, is currently scheduled for [***] (the "CRM12 Campaign"). As part of the transition from Proposal [***] to Proposal [***], Customer shall be entitled to cancel [***], that are part of the CRM12 Campaign up to [***] prior to the commencement of such CRM12 Campaign, without paying any cancellation fees to Lonza for such cancelled Batches. In such event, Lonza will deduct an amount of CHF [***] per cancelled Batch from the Price stated in the Purchase Order for the CRM12 Campaign. The remaining, un-cancelled Batches of the CRM12 Campaign shall be manufactured in accordance with Clause 2.3 and Clause 2.4 of the Original Agreement. For the sake of clarity, the Raw Materials purchased by Lonza for manufacturing the full CRM12 Campaign shall remain payable by Customer and shall not be (pro-rata) refunded in the event of (partly) cancellation of this Purchase Order.

	  
	  
	For illustrative purposes:

	  
	(i)
	in the event that Customer cancels the Purchase Order for the CRM12 shall pay an amount equal to the Price stated in Campaign in full, Customer that Purchase Order (i.e. [***] Batches and raw materials) CHF [***]; and 

	  
	(ii)
	minus an amount of in the event that Customer cancels one of the Batches of the Purchase Order for the CRM12 Campaign, Customer shall pay an amount equal to the Price stated in that Purchase Order minus an amount of CHF [***].

	  
	4.
	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Fifth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control unless Parties specifically deviated from such terms via this Fifth Amendment.

   

  			
	  
	5.
	No modification of or amendment to this Fifth Amendment, nor any waiver of any rights under this Fifth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.

  IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Fifth Amendment, effective as of the Fifth Amendment Effective Date.

  SUTROVAX INC

  By: /s/ Grant E. Pickering

  Name: Grant E. Pickering

  Title: President & CEO

  LONZA LTD

  By: /s/ Axel Evlev

  Name: Axel Evlev

  Title: Commercial Development

   

  

   

  Annex 1 - to Fifth Amendment

  Project Plan A-1.1

  {7 pages omitted}

  [***]

   

  

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

  ALL REFERENCES TO THE “SIXTH AMENDMENT” CONTAINED HEREIN SHOULD BE READ AS THE “FIFTH AMENDMENT.”

  SIXTH AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY AGREEMENT

  This Sixth Amendment (“Sixth Amendment”), which comes into effect on March 16, 2020 (the “Sixth Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and SutroVax Inc (“SutroVax”). This Sixth Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the “Original Agreement”). Lonza and SutroVax, hereafter referred to as a “Party” and collectively as the “Parties.”

  Whereas:

  				
	  
	1.
	Lonza and SutroVax entered into the Original Agreement, as amended, which the Parties now desire to amend;
	  

   

  				
	  
	2.
	The Parties wish to modify the payment terms as agreed in the Original Agreement, as amended.
	  

  Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:

  				
	  
	1.
	All capitalized terms used herein shall have the meaning set forth in the Original Agreement
	  

	  
	2.
	The Parties hereby agree that the current clause 8.3 shall be deleted in its entire and shall be replaced by the following clause:
	  

  "8.3 Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof (the “Initiation Payment”) and [***] upon Release of applicable Batches or completion of applicable Services (the “Completion Payment”), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch at cost plus a fee of [***]. Notwithstanding the above, Parties agree that in the event that Lonza does not complete stages of the IND enabling work, i.e. the stages necessary for Customer to submit the IND application, including in any event the Release of at least one (1) GMP Drug Product Batch plus one (1) month of GMP Drug Product stability testing before 31 December 2019 (the “IND-Enabling Activities”), Lonza shall for any stage that commences after 31 December 2019 or has not been completed by 31 December 2019, invoice the Initiation Payment for Products or Services upon commencement thereof. The Completion Payment for Products or Services shall be invoiced by Lonza upon release of such Products or completion of such Services, provided, however, that Customer shall not be required to effect any payment before either (i) within thirty (30) days following completion of all IND-Enabling Activities or (ii) 30 April 2021, whichever event occurs first. All invoices are strictly net and payment must be made [***]. Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement, including those Services to be performed after the Amendment Three Effective Date under Work Plan A-1, Work Plan A-2, Work Plan A-3 and Work Plan A-4.”

  				
	  
	3.
	All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Third Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.
	  

	  
	4.
	No modification of or amendment to this Sixth Amendment, nor any waiver of any rights under this Sixth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.
	  

   

  

   

  [Signatures on following page]

   

  

   

  IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Sixth Amendment, effective as of the Sixth Amendment Effective Date.

  			
	SUTROVAX INC
	  
	LONZA LTD

	  
	  
	  

	By: /s/ Grant Pickering
	  
	By: /s/ Michael Stanek

	  
	  
	  

	Name: Grant Pickering
	  
	Name Michael Stanek

	  
	  
	  

	Title: President & CEO
	  
	Title: General Counsel
  

	  
	  
	  

	  
	  
	  

	  
	  
	By: /s/ Bart van Aarnhem

	  
	  
	  

	  
	  
	Name Bart van Aarnhem

	  
	  
	  

	  
	  
	Title: Associate General Counsel

	  
	  
	  

   

   

  

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

  ALL REFERENCES TO THE “SEVENTH AMENDMENT” CONTAINED HEREIN SHOULD BE READ AS THE “SIXTH AMENDMENT.”

  SEVENTH AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY AGREEMENT 

  This Seventh Amendment (“Seventh Amendment”), which comes into effect as per April 1, 2021 (the “Seventh Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and Vaxcyte, Inc., having its principal place of business at 353 Hatch Drive, Foster City, CA 94404, USA (“Vaxcyte” or “Customer”). This Seventh Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended from time to time (the “Original Agreement”). Lonza and Vaxcyte, hereafter referred to as a “Party” and collectively as the “Parties.” 

  Whereas 

  		
	(A)
	Lonza and Vaxcyte have entered into the Original Agreement, as amended;

	(B)
	Vaxcyte now wishes to engage Lonza for the process development and manufacturing of [***], a [***] for the 24-valent vaccine against pneumococcal infections, to serve [***] to be manufactured in a larger scale at Lonza’s [***] facility;

	(C)
	The Parties wish to enter into this Seventh Amendment in order to (i) modify the payment terms as agreed in the Original Agreement, (ii) to ensure a slot reservation for Customer in Lonza's [***] facility and (iii) expeditiously negotiate in good faith an amendment to the Original Agreement regarding the [***] of the [***] by Lonza in [***] facility (the “Technology Transfer Amendment”). 

  Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:

  		
	1.
	All capitalized terms used herein shall have the meaning set forth in the Original Agreement.

   

  		
	2.
	The Parties hereby agree that the current clause 8.3 shall be deleted in its entirety and shall be replaced by the following clause:

   

  

  		
	  
	"8.3Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof (the “Initiation Payment”) and [***] upon Release of applicable Batches or completion of applicable Services (the “Completion Payment”), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch at cost plus a fee of [***]. Notwithstanding the above, Parties agree that in the event that Lonza does not complete stages of the IND enabling work, i.e. the stages necessary for Customer to submit the IND application, including in any event the Release of at least one (1) GMP Drug Product Batch plus one (1) month of GMP Drug Product stability testing before 31 December 2019 (the “IND-Enabling Activities”), Lonza shall for any stage that commences after 31 December 2019 or has not been completed by 31 December 2019, invoice the Initiation Payment for Products or Services upon commencement thereof. The Completion Payment for Products or Services shall be invoiced by Lonza upon release of such Products or completion of such Services, provided, however, that Customer shall not be required to effect any payment before either (i) within thirty (30) days following completion of all IND-Enabling Activities or (ii) 30 April 2021, whichever event occurs first. If all IND-Enabling Activities are not complete by 30 April 2021, Customer will pay an amount equal to 50% of the current Completion Payment totals. The rest of the 50% Completion Payment to be paid at the completion of all IND-Enabling Activities or 31, December 2021, whichever event occurs first. All invoices are strictly net and payment must be made [***]. Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement, including those Services to be performed after the Amendment Three Effective Date under Work Plan A-1, Work Plan A-2, Work Plan A-3 and Work Plan A-4.”

   

  		
	3.
	Upon execution of this Seventh Amendment, Customer agrees that it commits to a firm capacity reservation for Lonza’s manufacturing capacity as follows: Customer and Lonza agree that upon signature of this Seventh Amendment Lonza will issue an invoice to Customer for the reservation of capacity in the amount of [***] (the “Reservation Fee”). The payment terms as per the Original Agreement apply ([***]). The Reservation Fee will serve as a [***] reservation, by Lonza, of sufficient capacity within Lonza`s [***] facility in [***], personnel and resources to start the [***] for the [***] on behalf of Customer in [***] and commencement of manufacturing the first campaign of the [***] in the [***] facility in [***], subject to execution of the Technology Transfer Amendment within the timeframe set forth in clause 3.c) below and a successful technology transfer. Upon signature of the Technology Transfer Amendment, the Reservation Fee [***]. In the event, however, the Parties do not reach an agreement regarding the Technology Transfer Amendment before the term mentioned in clause 3.c) below, despite good faith negotiations, Lonza shall [***]. Moreover, in such case, Lonza may release such capacity and allocate it to other customers without liability to Customer. 

   

  		
	4.
	With respect to the negotiations and specific terms and conditions of the Technology Transfer Amendment, the Parties wish to record the following intentions:

   

  			
	  
	a)
	Upon execution of this Seventh Amendment, the Parties shall enter into good faith negotiations regarding the Technology Transfer Amendment. 

   

  

  			
	  
	b)
	The Parties intend that the Technology Transfer Amendment will include, all additional terms and activities or suitable to manufacturing the Product in Lonza’s [***] facility.

   

  			
	  
	c)
	The Parties intend to execute the Technology Transfer Amendment as soon as practicable, but in any event not later than [***]. In the event that the Parties are unable to sign the Technology Transfer Amendment by such date, despite good faith efforts by both Parties, a [***] extension for proper cause can be granted at the request of either Party. 

   

  		
	5.
	The Parties agree that any activities performed by Lonza while negotiations for the Technology Transfer Amendment are in process shall be performed in accordance with the Original Agreement as currently in force.

   

  		
	6.
	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Seventh Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control, unless Parties specifically deviated from such terms via this Seventh Amendment.

   

  		
	7.
	No modification of or amendment to this Seventh Amendment, nor any waiver of any rights under this Seventh Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 

   

  		
	8.
	This Seventh Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.

  [Signatures on following page]

   

  

   

  IN WITNESS WHEREOF, Customer and Lonza hereby enter into this Seventh Amendment, effective as of the Seventh Amendment Effective Date.

  			
	VAXCYTE. INC.
	  
	LONZA LTD

	  
	  
	  

	By: /s/ Grant Pickering
	  
	By: /s/ Marina Eiting

	  
	  
	  

	Name: Grant Pickering
	  
	Name Marina Eiting

	  
	  
	  

	Title: CEO
	  
	Title: Senior Program Manager

	  
	  
	  

	  
	  
	  

	  
	  
	  
By: /s/ Michael Stanek

	  
	  
	  

	  
	  
	Name Michael Stanek

	  
	  
	  

	  
	  
	Title: General Counsel

	  
	  
	  

   

   

  

   

  CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.

  EIGHTH AMENDMENT (VAXCYTE SEVENTH AMENDMENT) TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT 

  This Eighth Amendment (Vaxcyte Seventh Amendment) (the “Eighth Amendment”), which comes into effect on September 7, 2021 (the “Eighth Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and Vaxcyte, Inc., having its principal place of business at 353 Hatch Drive, Foster City, CA 94404, USA (“Vaxcyte” or “Customer”). This Eighth Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended (the “Original Agreement”). Lonza and Vaxcyte, hereafter referred to as a “Party” and collectively as the “Parties.” 

  Whereas:

  			
	  
	1.
	Lonza and Vaxcyte entered into the Original Agreement which the Parties now desire to amend;

	  
	2.
	The Parties wish to modify the payment terms as agreed in the Original Agreement, as amended.

  Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:

  		
	9.
	All capitalized terms used herein shall have the meaning set forth in the Original Agreement

	10.
	The Parties hereby agree that a new clause 7.3.4 shall be added to the Agreement with the following wording:

   

  		
	  
	"7.3.4Vaxcyte has decided to use certain critical Customer Materials (hereinafter referred to as “[***]”) for the manufacturing of Batches of the CRM12 intermediate in future campaigns, [***] as described in Deviation Report 774098 [***] (attached hereto as Appendix A). The [***] concerned are the following lots (the “[***]”):

	  
	  

	`
	1.    [***]

	  
	2.    [***]

	  
	3.    [***]

	  
	4.    [***]

	  
	5.    [***]

	  
	Notwithstanding any provision of this Clause 7.3, in the case of any Batch of the cell free produced CRM12 intermediate that [***], where [***], Customer will [***].”

   

  		
	11.
	All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Eighth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.

   

  		
	12.
	No modification of or amendment to this Eighth Amendment, nor any waiver of any rights under this Eighth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 

   

  

  		
	13.
	This Eighth Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.

  [Signatures on following page]

   

  

   

  IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Eighth Amendment, effective as of the Eighth Amendment Effective Date.

  			
	VAXCYTE, INC
	  
	LONZA LTD

	  
	  
	  

	By: /s/ Grant Pickering
	  
	By: /s/ Axel Erler

	  
	  
	  

	Name: Grant Pickering
	  
	Name: Axel Erler

	  
	  
	  

	Title: CEO
	  
	Title: Commercial Development

	  
	  
	  

	  
	  
	  

	  
By:
	  
  
	  
By: /s/ Michael Stanek

	  
	  
	  

	Name:
	  
	Name: Michael Stanek

	  
	  
	  

	Title:
	  
	Title: General Counsel

	  
	  
	  

   

   

  

   

  Appendix A

  Deviation Report 774098

  [***]

  {4 pages omitted}

   

  

   

  NINTH AMENDMENT (VAXCYTE EIGHTH AMENDMENT) TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT 

  This Ninth Amendment (Vaxcyte Eighth Amendment) (the “Ninth Amendment”), which comes into effect on October 15, 2021 (the “Ninth Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and Vaxcyte, Inc., having its principal place of business at 353 Hatch Drive, Foster City, CA 94404, USA (“Vaxcyte” or “Customer”). This Ninth Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended from time to time (the “Original Agreement”). Lonza and Vaxcyte, hereafter referred to as a “Party” and collectively as the “Parties.” 

  Whereas:

  			
	  
	3.
	Lonza and Vaxcyte entered into the Original Agreement which the Parties now desire to amend;

	  
	4.
	The Parties wish to extend the term of the Original Agreement with six (6) months.

  Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:

  		
	14.
	All capitalized terms used herein shall have the meaning set forth in the Original Agreement

	15.
	The Parties hereby agree that clause 14.1 of the Original Agreement shall be replaced in its entirety by the following new clause 14.1:

   

  		
	  
	“14.1 Term. This Agreement shall commence on the Effective Date and shall end on May 2, 2022, unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the "Term"). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.”

   

  		
	16.
	All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Ninth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.

	17.
	No modification of or amendment to this Ninth Amendment, nor any waiver of any rights under this Ninth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default. 

	18.
	This Ninth Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.

  [Signatures on following page]

   

  

   

  IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Ninth Amendment, effective as of the Ninth Amendment Effective Date.

  			
	VAXCYTE, INC
	  
	LONZA LTD

	By: /s/ Grant E. Pickering
	  
	By: /s/ Bart van Aarnhem

	Name: Grant E. Pickering
	  
	Name: Bart van Aarnhem

	Title: Chief Executive Officer
	  
	Title: Associate General Counsel

	  
	  
	  

	  
By:
	  
	  
By: /s/ Michael Stanek

	Name:
	  
	Name: Michael Stanek

	Title:
	  
	Title: General Counsel

   

   

  

   

  AMENDED AND RESTATED TENTH AMENDMENT (VAXCYTE NINTH AMENDMENT) TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT

  This Amended and Restated Tenth Amendment (Vaxcyte Ninth Amendment) (the “Tenth Amendment”), which retrospectively comes into effect on May 2, 2022 (the “Tenth Amendment Effective Date”), is made by and between Lonza Ltd (“Lonza”) and Vaxcyte, Inc., having its principal place of business at 825 Industrial Road, Suite 300, San Carlos, California 94070, USA (“Vaxcyte” or “Customer”). This Tenth Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended from time to time (the “Original Agreement”) and amends and restates in its entirety that certain Tenth Amendment dated May 2, 2022 (the “Original Tenth Amendment”) by and between Lonza and Vaxcyte. Lonza and Vaxcyte, hereafter referred to as a “Party” and collectively as the “Parties.” 

   

  Whereas:

   

  1.Lonza and Vaxcyte entered into the Original Agreement which the Parties now desire to amend;

   

  2.The Parties wish to extend the term of the Original Agreement by nine (9) months.

   

  Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:

   

  1.All capitalized terms used herein shall have the meaning set forth in the Original Agreement

   

  2.The Parties hereby agree that clause 14.1 of the Original Agreement shall be replaced in its entirety by the following new clause 14.1:

   

  “14.1 Term. This Agreement shall commence on the Effective Date and shall end on 2 February 2023, unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the "Term"). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.”

  3.All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Tenth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.

   

  4.No modification of or amendment to this Tenth Amendment, nor any waiver of any rights under this Tenth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.

   

   

  

  5.This Tenth Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.

   

  IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Tenth Amendment, effective as of the Tenth Amendment Effective Date.

   

  

   

  VAXCYTE, INC		            		 LONZA LTD

  By:	/s/ Grant E. Pickering        	                           By: /s/ Bart Van Aarnhem	

  Name: Grant E. Pickering	                                       Name: Bart Van Aarnhem	

  Title: CEO 	                                                               Title: Associate General Counsel	

   

  By:		                                                                By: /s/ Iwan Bertholjotti	

  Name:		                                                                 Name: Iwan Bertholjotti

  Title:	                                                             	     Title: Senior Director, Commercial 

                                                                                                   Development

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]